KEYNOTE-564
KEYNOTE-564: Updated Analysis of a Phase III Trial of Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Clear Cell Renal Cell Carcinoma

Released: February 02, 2024

Activity

Progress
1
Course Completed